Background. Epidemiological studies have demonstrated that obesity and low oestrogen receptor level adversely affect survival from breast cancer. Few studies have examined the joint effects of these variables. Methods. A cohort study was conducted in which 1169 breast cancer patients from the Northern Alberta Breast Cancer Registry were followed for an average of 4.4 years. A number of variables related to breast cancer incidence and prognosis were studied. Body mass index (BMI) was used as a proxy measure of obesity. Results. A Cox regression analysis resulted in a final model with terms for size of tumour, number of positive axillary nodes, oestrogen receptor level, BMI, and age at diagnosis, plus an interaction term for node status and BMI. Having relatively less oestrogen receptor increased the hazard ratio by 1.8 (95% CI : 1.4-2.3); for women with no positive nodes, being in the highest quartile of BMI increased the hazard ratio by 2.5 (95% CI : 1.2-5.2) compared to the lowest quartile. Conclusions. BMI and oestrogen receptor level independently influence survival from breast cancer, but BMI affects survival only in patients with no positive axillary nodes.
A number of epidemiological studies have provided evidence that breast cancer patients who are overweight at the time of diagnosis have a relatively poor prognosis.
1-11 Not all investigators have confirmed this association. [12] [13] [14] [15] [16] [17] One explanation for a possible effect of body weight on the course of breast cancer is that in obese women there may be enhanced conversion in the adipose tissue of the oestrogen precursor androstenedione to oestrone causing accelerated growth of the tumour. 18 A measurement which is being reported in survival studies of breast cancer patients is tumour oestrogen receptor level. An elevated level has been shown to correlate with better prognosis. [19] [20] [21] [22] Since obesity and oestrogen receptor level may both have a bearing on hormonal make-up, the question arises as to what might be the independent and joint effects of these variables on prognosis in breast cancer. A few studies have investigated this issue. Hebert et al. 7 found an effect on recurrence-free survival of body mass index (defined below), but not oestrogen receptor level. Senie 9 et al. defined obesity using standard insurance tables and found that recurrence-free survival was reduced in obese patients, but that outcome was not influenced by oestrogen receptor level. Williams et al. 15 studied patients with advanced disease and did not observe an effect on survival of weight or oestrogen receptor level. In the recent study by Obermair et al. 17 neither obesity nor oestrogen receptor level were related to disease-free survival.
In this paper we report a cohort study of breast cancer mortality. Subjects were drawn from a populationbased registry and data items included a range of variables that have been related to breast cancer incidence or prognosis. Of particular interest was the relationship of body mass index and oestrogen receptor level to disease-specific survival.
1971. It has as catchment area the northern part of Alberta, including the provincial capital of Edmonton. Although registration of breast cancer patients is no longer compulsory in Alberta, virtually all women in the catchment area treated for this disease are placed on the Registry. 23 Follow-up is maintained through an annual examination or, in cases where this is not possible, by correspondence with the patient's physician. Additionally, Alberta Vital Statistics records are reviewed and obituaries in local newspapers are screened for deaths of Registry subjects. Provincial cancer registries in Canada have reciprocal arrangements for sharing records, and so Alberta patients who move to another province and seek treatment will become known to the Registry. Loss of contact occurs for a small proportion of registrants, usually after several years of follow-up.
The data elements routinely collected by the Registry and analysed in this study are the following: personalage (at diagnosis), height, weight, menopausal status, parity, birth control use, breast feeding; disease-size of tumour, number of positive axillary nodes, clinical stage, oestrogen receptor level, progesterone receptor level, histology; treatment-surgery, chemotherapy, hormone therapy, radiotherapy. Height and weight were measured by clinic nurses.
To be included in the cohort, patients had to be registered during the 12 year period 1978-1989. The earlier cutoff was adopted since prior to this time oestrogen receptor levels were not routinely measured. Women with advanced disease were excluded from the cohort by restricting to the following TNM categories: T0-T3; N0-N1; and M0. This includes all stage I and II cases and a subset of stage III cases. The registration year requirement and TNM restrictions reduced the number of eligible subjects to 3429. Cases were then dropped from the cohort if they had missing values for any of the variables listed above. Subjects who did not have axillary nodes removed for any reason were also excluded. The variables of particular importance to the study were size of tumour, number of positive axillary nodes, oestrogen receptor level, age, height, and weight. Missing values for these variables reduced the cohort to 1257 subjects. After taking into account missing values for the remaining variables the final cohort size was 1169. By construction the final dataset had no missing values.
We compared the group of 3429 subjects with the subgroup of 1169 according to key variables. There were no marked differences with respect to age, size of tumour, number of positive nodes or oestrogen receptor level. In the larger group, 40.9% and 52.6% were in stages I and II, respectively, while for the subgroup comprising the final cohort the proportions were 32.1% and 61.6%, respectively. With the possible exception of stage of disease (and this is accounted for in the data analysis by including size of tumour and number of positive nodes) the 1169 cases appear to be a representative sample of Registry subjects.
All variables were treated as categorical, in particular, age (Ͻ40, 40-49, 50-59, 60-69, 70+), size of tumour in mm (Ͻ21, 21-50, 51+), number of positive nodes (0, 1-3, 4+) and oestrogen receptor level in fmol protein per mg cytosol protein (Ͻ10, 10+). Chemotherapy, radiotherapy and hormonal therapy variables were dichotomized according to whether the intervention was given or not. Type of surgery was categorized into no surgery, local resection (lumpectomy, segmental resection) or mastectomy (total, extended total, modified radical). Body mass index (BMI), defined as weight (in kilograms) divided by the square of height (in metres), was used as a proxy measurement for obesity. 24 We constructed three BMI categories by creating quartiles and then combining the two middle quartiles. The cutoff for the upper quartile was 28.9 which corresponds closely to the value of 28.5 used to define obesity in a Canadian national survey. 25 Follow-up continued until the end of 1990, with death from breast cancer as the endpoint of interest. Those subjects not known to have died were presumed to be alive at the end of the period of observation for the purposes of survival analysis. Death from a cause other than breast cancer or survival to the end of 1990 were considered censoring events. We estimate that 7.3% of study subjects were lost to follow-up. Under the assumption that all these women in fact remained alive until the end of 1990, a conservative estimate is that 3.9% of the maximum person-years of observation were lost because of censoring.
Survival analysis was performed using the KaplanMeier method 26 and Cox regression. 27 The appropriateness of the proportional hazards assumption was checked using log(-log) plots. 28 The EGRET statistical package 29 was used for calculations. Variables were screened using Kaplan-Meier survival curves and Cox regression, with the variable under study as a single main effect. Multivariate models were built in a stepwise hierarchical fashion, testing the statistical significance of added terms using the likelihood ratio method. 30 The variables size of tumour, number of positive nodes, and oestrogen receptor level were expected to be strongly predictive of survival. The main analytical question was whether obesity (as measured by BMI) was also related to survival after adjusting for the preceding variables. Several investigators have found excessive weight to be predictive of worse survival, but primarily in that subgroup of patients with an otherwise favourable covariate profile.
1,2,6,7,9 Thus, we were interested in exploring the two-way interactions between BMI and each of the variables size of tumour, number of positive nodes, and oestrogen receptor level.
RESULTS
The median age of patients at diagnosis was 56.1 years (range 25-98). The average and median lengths of follow-up were 4.35 and 3.62 years, respectively (range 0.5-11.7). A majority of the cohort (61%) was postmenopausal. Tumour histology was classified according to the International Classification of Diseases for Oncology, Second Edition 31 and three broad categories were defined: infiltrating duct carcinoma (76%), infiltrating lobular carcinoma (11%), and other (13%). Frequency distributions for selected variables are given in detail in Table 1 . The median tumour size was 20 mm, and just over half (54%) of the patients were node negative. The preceding two pathologic variables were employed in the survival analyses in preference to the more subjective clinical stage. As can be seen from Table 1 , almost one-third (32%) of patients were in stage I, and just under two-thirds (62%) were in stage II, with the remainder in stage III. With the cut-off for oestrogen receptor level set at 10 fmol, 67% of subjects were in the higher range. Table 1 also shows the distribution across BMI categories. For example, 39% of subjects under the age of 40 had a BMI of less than 22.8. Elevated BMI correlates positively with older age, more advanced stage, larger tumour size, greater number of positive nodes, and elevated oestrogen receptor level.
There were 295 deaths among the 1169 cohort members, 244 (83%) of which were due to breast cancer. With death from breast cancer as the endpoint, the KaplanMeier estimate of 10-year survival was 58.5% (95% confidence interval : 52.4-64.1); with death from any cause as the endpoint the result was 52.3%. Figure 1 shows the Kaplan-Meier survival curves for the entire cohort for the first 10 years of follow-up stratified by BMI. Note that the vertical axis starts at 0.50. The quotients in the legend box are the number of breast cancer deaths for the entire period of follow-up divided by the number at risk. Although the relationships are obscured at the extremes of the follow-up period, Figure 1 demonstrates a trend of poorer survival with increasing BMI.
All of the variables listed at the outset were tested in the Cox regression analysis except for height and weight (which were used to define BMI). Variables were first analysed individually, that is, as main effects. Of the personal variables listed (excluding height and weight) only age (P = 0.03) was statistically significant. Of the disease variables, size of tumour, number of positive nodes, clinical stage, oestrogen receptor level, and progesterone receptor level were all highly statistically significant (each with P Ͻ 0.001). Histology of the tumour was not statistically significant (P = 0.34). Of the treatment variables, chemotherapy (P = 0.02) and radiotherapy (P = 0.02) were statistically significant, but not surgery (P = 0.95) or hormonal therapy (P = 0.23). Somewhat surprisingly, in view of Figure 1 , BMI was not statistically significant as a main effect (P = 0.17).
Model building proceeded in a stepwise fashion. Size of tumour, number of positive nodes and oestrogen receptor level were highly statistically significant no matter which other variables were included in the model. With these three variables accounted for, clinical stage, progesterone receptor level and radiotherapy ceased to be statistically significant. Chemotherapy retained a marginal level of statistical significance (P = 0.04), but in view of the findings for the other treatment variables, chemotherapy was also dropped from the analysis. It seems that the strong correlation between stage of disease and choice of treatment led to the low predictive value of the treatment variables in this analysis. BMI did not emerge as statistically significant until it was interacted with other variables which were of major prognostic importance. This is consistent with the remarks made earlier that excess weight has an influence on breast cancer patients only when there is an otherwise favourable picture. The variables in the final Cox regression model were the following: size of tumour, number of positive nodes, oestrogen receptor level, age, BMI, and an interaction term for number of positive nodes and BMI. Table 2 shows the hazard ratios and associated confidence intervals. Increasing size of tumour, greater number of positive nodes, and low oestrogen receptor level all correlate with poorer survival. As can be seen from the confidence intervals, these findings are statistically significant. For age, there is a curvilinear pattern, with women in the 40-59 range demonstrating relatively better survival compared with those at the youngest and oldest ages. However, this finding must be viewed with caution since the confidence intervals overlap. Overall, age is statistically significant (P = 0.03), but only for the 50-59 category does the confidence interval not include the null value. The final panel of the table shows the hazard ratios corresponding to the nodes × BMI interaction term. The entries have the following Table 2 , the results in Table 3 were calculated in order to illustrate the interaction better.
Hazard ratios were here defined relative to the lowest BMI category. Increasing BMI correlates with an elevated mortality risk, but only for women with no positive nodes. When positive nodes are present there is no effect of BMI on prognosis. Figure 2 shows the KaplanMeier survival curves for BMI categories, but restricted to subjects with no positive nodes.
DISCUSSION
We conducted a cohort study of 1169 breast cancer patients identified through the Northern Alberta Breast Cancer Registry, a population-based information system that has been in operation since 1971. The average length of follow-up was 4.4 years. Death from breast cancer was the endpoint of interest. The Registry contains a number of variables that are related to the risk of developing breast cancer and prognosis following a diagnosis. The aim of the study was to assess the independent and joint effects on survival of oestrogen receptor level and body mass index. In a Cox regression analysis, oestrogen receptor level and BMI were both statistically significant as main effects, but no interaction term for these variables was required, indicating that the effects of these variables are independent. Size of tumour, number of positive nodes, and age group were also statistically significant, as was the interaction term for number of positive nodes and BMI. The gradients of risk were as expected for oestrogen receptor level, BMI, size of tumour, and number of positive nodes. In particular, those subjects with BMI in the upper three quartiles had a mortality risk that was more than double that for cases in the lowest quartile. The pattern across age groups is difficult to interpret, but there is a suggestion that women in the 40-59 age range have a relatively better prognosis compared with women who are younger or older. A detailed examination of the interaction between number of positive nodes and BMI showed that the risk associated with increasing BMI was to be found only in patients with no positive nodes.
As noted in the introduction there are numerous studies which have demonstrated that being overweight at the time of diagnosis is predictive of a relatively poor prognosis from breast cancer, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and that not all investigators who examined this relationship have found such an association. [12] [13] [14] [15] [16] [17] Research has also been published showing that elevated levels of oestrogen receptor are related to increased survival. [19] [20] [21] [22] A few studies have looked at these variables together. Hebert et al. 7 and Senie et al. 9 found that being overweight was predictive of outcome, but that oestrogen receptor level was not a prognostic indicator. Williams et al. 13 and Obermair et al. 17 did not find an effect for either variable. Of all the papers cited, our study is most closely related to that of Senie et al. 9 in terms of sample size, sampling frame, and variables available for analysis. In that study, obesity was defined using weight and height, with reference to standard insurance tables. In the present study, BMI was used as a proxy measure of obesity. Senie et al. 9 performed a Cox regression and found that obesity was statistically significant after controlling for size of tumour, number of positive nodes, age at diagnosis, and adjuvant chemotherapy. Oestrogen receptor level was not a statistically significant variable. In our study, low oestrogen receptor level increased the hazard ratio by a factor of 1.8. Thus, of the studies that have looked at the joint effects of obesity and oestrogen receptor level, 7,9,13,17 the present one is alone in demonstrating the prognostic effect of oestrogen receptor.
We found an interaction between number of positive nodes and BMI in that elevated BMI was predictive of worse survival, but only in the node negative category. Similar findings have been reported by others.
1, 2, 6, 7, 9 The implication is that the harmful consequences of being overweight are small in comparison to such powerful clinical factors as tumour size and node status. Consequently, BMI cannot be considered a key factor in the determination of type of therapy.
The mechanism by which being overweight might cause increased mortality from breast cancer is not well understood. An explanation that has been offered is that the conversion of the oestrogen precursor androstenedione to oestrone results in stimulation of the breast tumour, and this phenomenon is more pronounced in the altered hormonal environment of obese women. 18 In our data there was a tendency for women with a larger BMI to present at a later stage of disease. However, the present study is concerned with outcome following a diagnosis. Since the multivariate analysis accounts for node status and tumour size, the effect of BMI on survival is not likely to be an artefact resulting from an association of BMI with these other established predictors of survival. Despite the lack of understanding of the physiology underlying the relationship, the empirical evidence shows that overweight women with breast cancer have a relatively poor survival experience, at least when the disease is at an early stage. 
